Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18364
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSfagos, C.en
dc.contributor.authorMakis, A. C.en
dc.contributor.authorChaidos, A.en
dc.contributor.authorHatzimichael, E. C.en
dc.contributor.authorDalamaga, A.en
dc.contributor.authorKosma, K.en
dc.contributor.authorBourantas, K. L.en
dc.date.accessioned2015-11-24T18:52:09Z-
dc.date.available2015-11-24T18:52:09Z-
dc.identifier.issn1352-4585-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18364-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectBiological Markers/metabolismen
dc.subjectFemaleen
dc.subjectFerritins/*blooden
dc.subjectHumansen
dc.subjectIron/metabolismen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMultiple Sclerosis, Chronic Progressive/*blooden
dc.subjectMultiple Sclerosis, Relapsing-Remitting/*blooden
dc.subject*Oxidative Stressen
dc.subjectReceptors, Transferrin/*blooden
dc.subjectSeverity of Illness Indexen
dc.subjectSolubilityen
dc.subjectTransferrin/*metabolismen
dc.titleSerum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patientsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15957506-
heal.identifier.secondaryhttp://msj.sagepub.com/content/11/3/272.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractOver the last few years, increased evidence has supported the role of iron dysregulation in the pathogenesis of multiple sclerosis (MS), as iron is essential for myelin formation and oxidative phosphorylation. We studied indices of iron metabolism, such as serum iron, ferritin, transferrin and soluble transferrin receptor (sTFR) levels in 27 MS patients. Seven patients had chronic progressive active disease (CP-A), six had chronic progressive stable (CP-S), ten had relapsing remitting active (RR-A) and four had relapsing-remitting stable (RR-S) disease. sTFR levels were found to be significantly higher in CP-A (P = 0.021) and RR-A (P < 0.004) patients than in controls. sTFR levels were also elevated in CP-S patients but did not reach significance (P = 0.064). sTFR values in RR-S patients were comparable to those found in controls (P = 0.31). Ferritin levels were significantly elevated only in CP-A patients (P < 0.002). Patients of the CP group had significantly higher ferritin values than the RR patients (P < 0.004). Haemoglobin values as well as iron and transferrin levels were within normal limits in all patients. In conclusion, the increased serum sTFR and ferritin levels in nonanaemic MS patients with active disease reflect the increased iron turnover. The mild elevation of sTFR levels in CP-S patients may indicate active inflammation with ongoing oxidative damage that is not detectable by history or examination.en
heal.journalNameMult Scleren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Sfagos-2005-Serum ferritin, tran.pdf91.7 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons